Ambrosia maritima L. (family Asteraceae) is an annual herb widely distributed throughout the Mediterranean region and Africa. The herb is employed in folk medicine for the treatment of many ailments. Herein, we report a comprehensive investigation of the diverse biological potential of two sesquiterpene lactones, damsin and neoambrosin, isolated from Ambrosia maritima. 1D and 2D NMR and HR-ESI-MS/MS were employed to characterize the chemical structures of both compounds. In order to identify biological targets of both compounds we investigated their potential affinity for peroxisome proliferator-activated receptors (PPARs) and transient receptor potential (TRP) channels, which are pleiotropic classes of receptors implicated in essential functions of the body. This was investigated using a luciferase assay and a calcium fluorometric assay. A carbonic anhydrase inhibition assay was also performed using stopped flow CO2 hydrase spectrophotometric assay. Our analysis revealed that unlike damsin, neoambrosin showed a selective partial agonist effect on PPARγ receptors and TRPA1 channels. Its binding mode was investigated through in silico analysis. Both compounds showed no affinity for the tested carbonic anhydrases. Overall, our study details the chemical properties of neoambrosin and damsin and highlights neoambrosin as novel, cost-effective partial agonist of PPARɣ and TRPA1 receptors despite additional in vivo studies are needed to elucidate its biological and pharmacological properties.

A series of novel 1,2,4-oxadiazole-based derivatives were synthesized and evaluated for their potential anti-Alzheimer disease activity. The results revealed that compounds 2b, 2c, 2d, 3a, 4a, 6, 9a, 9b, and 13b showed excellent inhibitory activity against acetylcholinesterase (AChE) with IC50 values in the range of 0.0158 to 0.121 μM. They were 1.01 to 7.78 times more potent than donepezil (IC50 = 0.123 μM). The newly synthesized compounds exhibited lower activity towards butyrylcholinesterase (BuChE) when compared to rivastigmine. Compounds 4b and 13b showed the most prominent inhibitory potential against BuChE with IC50 values of 11.50 and 15 μM, respectively. Moreover, 4b, and 9b were found to be more potent antioxidant agents (IC50 values of 59.25, and 56.69 μM, respectively) in comparison with ascorbic acid (IC50 = 74.55 μM). Compounds 2b and 2c exhibited monoamine oxidase-B (MAO-B) inhibitory activity with IC50 values of 74.68 and 225.48 μM, respectively. They were 3.55 and 1.17 times more potent than biperiden (IC50 = 265.85 μM). The prominent interactions of the compounds with the AChE active site can be used to computationally explain the high AChE inhibitory activity. The results unveiled 1,2,4-oxadiazole derivatives 2c and 3a as multitarget anti-AD agents. The predicted ADME properties for compounds 2b and 4a were satisfactory, and 4a had the highest likelihood of crossing the blood–brain barrier (BBB), making it the optimum compound for future optimization.

In the current study, we developed a simple and biocompatible method for producing core–shell nanoparticles (NPs). Citrate auto combustion and green procedures were used to create core–shell Ag/CoGd0.025Er0.05Fe1.925O4 (Ag/CGEFO) sample with an average crystallite size of 26.84 nm. The prepared samples were characterized via different structural techniques, such as x-ray diffraction (XRD), Raman Spectroscopy (RS), High-Resolution Transmission Electron Microscopy, and Energy Dispersive x-ray analysis. These analyses were utilized to characterize and confirm the successful formation of the core–shell architecture. For core–shell NPs, all peaks of Ag and CGEFO ferrite are detected in the XRD, confirming the co-presence of the ferrite spinel phase and the cubic Ag phase. The magnetic hysteresis curves demonstrate typical hard ferri-magnetic behavior along with maximum magnetic saturation values up to 53.74 emu g−1 for the CGEFO sample, while an enhanced coercivity is detected for the coated sample. Moreover, the width of the hysteresis loop is increased for the Ag/CGEFO sample compared to the uncoated one. This indicates that the addition of Ag as a shell increases magneto crystalline anisotropy. Moreover, the E g of uncoated CGEFO is equal to 1.4 eV, increasing to 3.6 eV for coated ones. This implies the influence of CGEFO is diminished when the surface is coated with Ag (shell), and the reflectance of the Ag/CGEFO core–shell is nearly dependent on the reflectance of the Ag shell layer. Consequently, the Ag/CGEFO can be used as a light shielding substance.

In the current study, we developed a simple and biocompatible method for producing core–shell nanoparticles (NPs). Citrate auto combustion and green procedures were used to create core–shell Ag/CoGd0.025Er0.05Fe1.925O4 (Ag/CGEFO) sample with an average crystallite size of 26.84 nm. The prepared samples were characterized via different structural techniques, such as x-ray diffraction (XRD), Raman Spectroscopy (RS), High-Resolution Transmission Electron Microscopy, and Energy Dispersive x-ray analysis. These analyses were utilized to characterize and confirm the successful formation of the core–shell architecture. For core–shell NPs, all peaks of Ag and CGEFO ferrite are detected in the XRD, confirming the co-presence of the ferrite spinel phase and the cubic Ag phase. The magnetic hysteresis curves demonstrate typical hard ferri-magnetic behavior along with maximum magnetic saturation values up to 53.74 emu g−1 for the CGEFO sample, while an enhanced coercivity is detected for the coated sample. Moreover, the width of the hysteresis loop is increased for the Ag/CGEFO sample compared to the uncoated one. This indicates that the addition of Ag as a shell increases magneto crystalline anisotropy. Moreover, the E g of uncoated CGEFO is equal to 1.4 eV, increasing to 3.6 eV for coated ones. This implies the influence of CGEFO is diminished when the surface is coated with Ag (shell), and the reflectance of the Ag/CGEFO core–shell is nearly dependent on the reflectance of the Ag shell layer. Consequently, the Ag/CGEFO can be used as a light shielding substance.

Background: Erector Spinae Plane Block (ESPB) is a simple and safe analgesic technique to relieve thoracotomy pain, but we need to increase the duration of analgesia with a single shot. so, we compared the analgesic efficacy of Dexmedetomidine (DEX) versus ketamine as an adjuvant to bupivacaine ESPB in children scheduled for thoracotomy cardiothoracic surgeries.Methods: 90 children aged 3 to 36 months, scheduled for thoracotomy cardiothoracic surgeries, were divided into group Bupivacaine (B) (n=30) and received ESPB using 0.5 ml/kg bupivacaine 0.25% in 15 ml saline. Group Bupivacaine-ketamine (BK) (n=30) received the same as group B plus ketamine 2 mg/kg. Group Bupivacaine-Dexamedetomedine (BD) received the same as group B plus dex 1 μg/kg. The time to first rescue analgesia, perioperative hemodynamics, postoperative pain intensity, total consumption of opioids, and frequency of complications were measured.Results: The addition of dexmedetomidine and ketamine to bupivacaine resulted in a significant prolongation of postoperative analgesia duration (16.4 ± 3.79 hr,95%CI: 14.951:17.783, P<0.001) and(10.1 ± 2.36 hr,95%CI: 9.184:10.949, P<0.001), respectively compared with 0.5% bupivacaine alone (5.2 ± 1.26 hr. 95%CI: 4.714:5.625). postoperative analgesia duration was more prolonged in the BD group than in the Bk group( P<0.001). with lower perioperative opioid consumption, better hemodynamic profile, and better predictive indexes (extubation time and hospital stay) in the BD and BK groups than in the B group. Conclusion: Dexmedetomidine as an adjuvant to bupivacaine provides a longer duration of analgesia as compared to ketamine without any significant side effects.

The ongoing need for hematologists is not met in many parts of the world. The hematology rotation during internal medicine residency is an opportunity to attract more physicians to the hematology field. This study aimed to assess the impact of a hematology rotation on internal medicine residents’ interest in considering a hematology career.

Tuberculosis is a global public health concern. Earlier reports suggested the emergence of high rates of drug resistant tuberculosis in Egypt. This study included 102 isolates of Mycobacterium tuberculosis collected from two reference laboratories in Cairo and Alexandria. All clinical isolates were sub-cultured on Löwenstein–Jensen medium and analyzed using both BD BACTEC MGIT 960 SIRE Kit and standard diffusion disk assays to identify the antibiotic sensitivity profile. Extracted genomic DNA was subjected to whole genome sequencing (WGS) using Illumina platform. Isolates that belong to lineage 4 represented > 80%, while lineage 3 represented only 11% of the isolates. The percentage of drug resistance for the streptomycin, isoniazid, rifampicin and ethambutol were 31.0, 17.2, 19.5 and 20.7, respectively. Nearly 47.1% of the isolates were sensitive to the four anti-tuberculous drugs, while only one isolate was resistant to all four drugs. In addition, several new and known mutations were identified by WGS. High rates of drug resistance and new mutations were identified in our isolates. Tuberculosis control measures should focus on the spread of mono (S, I, R, E)- and double (S, E)-drug resistant strains present at higher rates throughout the whole Nile Delta, Egypt.

BACKGROUND: Children with sickle cell disease (SCD) who are chronically transfused often, require iron chelation therapy. There are limited data that allow for comparison of the efficacy and safety of the iron chelator deferiprone versus deferoxamine in children with SCD.

METHODS: This post hoc analysis of the phase 3b/4, randomized, open-label FIRST (Ferriprox in Patients with IRon Overload in Sickle Cell Disease Trial) study (NCT02041299) included patients 17 years and younger with SCD or other anemias receiving deferiprone or deferoxamine.

RESULTS: Overall, 142 patients were evaluated; mean ages were 10.5 and 11.7 years in the deferiprone and deferoxamine groups, respectively. At 12 months: mean change from baseline in liver iron concentration was -3.3 mg/g dry weight (dw) with deferiprone and -3.4 mg/g dw with deferoxamine (p = .8216); relative mean change (coefficient of variation %) in log cardiac T2* magnetic resonance imaging was 1.02 (21.8%) with deferiprone and 0.95 (19.5%) with deferoxamine (p = .0717); and the mean (standard error) change in serum ferritin levels was -133.0 (200.3) μg/L with deferiprone and -467.1 (244.1) μg/L with deferoxamine (p = .2924). The most common deferiprone-related adverse events (AEs) were upper abdominal pain (20.2%), vomiting (13.8%), pyrexia (9.6%), decreased neutrophil count (9.6%), increased alanine aminotransferase (ALT; 9.6%), and increased aspartate aminotransferase (AST; 9.6%). All cases of increased ALT, increased AST, and neutropenia resolved, most without intervention.

CONCLUSIONS: This post hoc analysis of pediatric patients from FIRST corroborated previous findings in adults that deferiprone is comparable to deferoxamine in reducing iron overload. No new safety concerns were observed. Deferiprone is an oral chelation option that could improve adherence and outcomes in children.